HK1054375A1 - 二氮雙雜環中樞神經系統活性劑 - Google Patents

二氮雙雜環中樞神經系統活性劑 Download PDF

Info

Publication number
HK1054375A1
HK1054375A1 HK03104885.7A HK03104885A HK1054375A1 HK 1054375 A1 HK1054375 A1 HK 1054375A1 HK 03104885 A HK03104885 A HK 03104885A HK 1054375 A1 HK1054375 A1 HK 1054375A1
Authority
HK
Hong Kong
Prior art keywords
nervous system
active agents
central nervous
system active
diazabicyclic
Prior art date
Application number
HK03104885.7A
Other languages
English (en)
Chinese (zh)
Inventor
R. Schrimpf Michael
R. Tietje Karin
B. Toupence Richard
Ji Jianguo
Basha Anwer
H. Bunnelle William
F. Daanen Jerome
M. Pace Jennifer
B. Sippy Kevin
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/833,914 external-priority patent/US6809105B2/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of HK1054375A1 publication Critical patent/HK1054375A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK03104885.7A 2000-04-27 2001-04-27 二氮雙雜環中樞神經系統活性劑 HK1054375A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55994300A 2000-04-27 2000-04-27
US09/833,914 2001-04-12
US09/833,914 US6809105B2 (en) 2000-04-27 2001-04-12 Diazabicyclic central nervous system active agents
PCT/US2001/013798 WO2001081347A2 (en) 2000-04-27 2001-04-27 Diazabicyclic central nervous system active agents

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
HK11107946.7A Division HK1154234A (en) 2000-04-27 2003-07-08 Diazabicyclic central nervous system active agents
HK11107947.6A Division HK1154235A (en) 2000-04-27 2003-07-08 Diazabicyclic central nervous system active agents

Related Child Applications (2)

Application Number Title Priority Date Filing Date
HK11107946.7A Addition HK1154234A (en) 2000-04-27 2003-07-08 Diazabicyclic central nervous system active agents
HK11107947.6A Addition HK1154235A (en) 2000-04-27 2003-07-08 Diazabicyclic central nervous system active agents

Publications (1)

Publication Number Publication Date
HK1054375A1 true HK1054375A1 (zh) 2003-11-28

Family

ID=27072208

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03104885.7A HK1054375A1 (zh) 2000-04-27 2001-04-27 二氮雙雜環中樞神經系統活性劑

Country Status (22)

Country Link
EP (3) EP1284976A2 (https=)
JP (2) JP4981232B2 (https=)
KR (4) KR100947188B1 (https=)
CN (3) CN101935322A (https=)
AR (1) AR030421A1 (https=)
AU (2) AU2001266559C1 (https=)
BG (2) BG66151B1 (https=)
BR (1) BR0107246A (https=)
CA (2) CA2683045A1 (https=)
CZ (4) CZ302795B6 (https=)
HK (1) HK1054375A1 (https=)
HU (1) HUP0300602A3 (https=)
IL (3) IL152231A0 (https=)
MX (1) MXPA02010594A (https=)
MY (3) MY137020A (https=)
NO (1) NO324250B1 (https=)
NZ (1) NZ521734A (https=)
PE (1) PE20011305A1 (https=)
PL (2) PL358340A1 (https=)
SK (2) SK287658B6 (https=)
TW (4) TWI311137B (https=)
WO (1) WO2001081347A2 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1382339B1 (en) 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
SE0100326D0 (sv) * 2001-02-02 2001-02-02 Astrazeneca Ab New compounds
KR100678800B1 (ko) 2002-11-21 2007-02-05 화이자 프로덕츠 인코포레이티드 3-아미노-피페리딘 유도체 및 그의 제조 방법
US7354937B2 (en) 2004-05-21 2008-04-08 Abbott Laboratories (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
US20040242641A1 (en) 2003-05-27 2004-12-02 Buckley Michael J. (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US20050261348A1 (en) * 2004-05-21 2005-11-24 Buckley Michael J (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050065178A1 (en) * 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20050171079A1 (en) 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
JP2007535553A (ja) 2004-04-29 2007-12-06 アボット・ラボラトリーズ アミノ−テトラゾール類縁体および使用方法
US7351833B2 (en) 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
AU2006327300A1 (en) * 2005-12-20 2007-06-28 Astrazeneca Ab Substituted Cinnoline derivatives as GABAa-receptor modulators and method for their synthesis
US20070184490A1 (en) * 2006-01-17 2007-08-09 Marleen Verlinden Neuronal nicotinic receptor ligands and their use
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
US20100234349A1 (en) 2006-09-04 2010-09-16 Olsen Gunnar M Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8076350B2 (en) 2006-12-22 2011-12-13 Abbott Laboratories Spirocyclic azaadamantane derivatives and methods of use
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
ATE509931T1 (de) 2007-03-23 2011-06-15 Abbott Lab Azaadamantanester- und carbamatderivate sowie anwendungsverfahren dafür
RU2486187C2 (ru) 2007-09-11 2013-06-27 Эбботт Лэборетриз N-ОКСИДЫ ОКТАГИДРО-ПИРРОЛО[3,4-b]ПИРРОЛА
AR069126A1 (es) 2007-10-31 2009-12-30 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa
EP2231672B1 (en) * 2007-11-21 2014-12-17 AbbVie Inc. BIARYL SUBSTITUTED DIAZABICYCLOHEPTANE DERIVATIVES AS nAChR MODULATORS
WO2010009775A1 (de) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
EP2231644B1 (de) 2007-12-07 2014-01-15 AbbVie Deutschland GmbH & Co KG 5,6-Disubstitutierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
JP5701607B2 (ja) 2007-12-07 2015-04-15 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミドメチル置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
KR20100097195A (ko) 2007-12-07 2010-09-02 애보트 게엠베하 운트 콤파니 카게 ５－할로겐－치환된 옥스인돌 유도체 및 바소프레신－의존성 질병을 치료하기 위한 이의 용도
ES2380398T3 (es) 2007-12-18 2012-05-11 Actelion Pharmaceuticals Ltd. Derivados 5-aminociclilmetil-oxazolidin-2-ona
SI2336125T1 (sl) 2008-04-11 2013-04-30 Janssen Pharmaceutica N.V. Tiazolopiridin-2-iloksi-fenil in tiazolopirazin-2-iloksi-fenil amini kot modulatorji levkotrien a4 hidrolaze
US8148408B2 (en) 2008-05-09 2012-04-03 Abbott Laboratories Selective substituted pyridine ligands for neuronal nicotinic receptors
US8263632B2 (en) * 2009-03-24 2012-09-11 Vertex Pharmaceuticals Incoporated Aminopyridine derivatives having Aurora A selective inhibitory action
CN102459251B (zh) 2009-05-14 2015-05-20 詹森药业有限公司 作为白三烯a4水解酶的调节剂的具有两个稠合双环杂芳基部分的化合物
EP2435080A2 (en) 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
WO2010151815A2 (en) 2009-06-25 2010-12-29 Abbott Laboratories 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
PT2473049T (pt) 2009-09-04 2019-03-04 Sunesis Pharmaceuticals Inc Inibidores de tirosina quinase de bruton
WO2011050200A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
ES2585806T3 (es) 2009-10-23 2016-10-10 Janssen Pharmaceutica N.V. Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
KR101655787B1 (ko) 2014-05-08 2016-09-22 대우조선해양 주식회사 선박의 하이브리드 공기조화시스템 및 그 방법, 그리고 이를 포함하는 선박 또는 해양구조물
KR20160021679A (ko) 2014-08-18 2016-02-26 대우조선해양 주식회사 극저온 환경의 장비용 히팅장치 및 방법 그리고 이를 구비하는 선박
DK3212637T3 (da) 2014-10-31 2021-07-12 Indivior Uk Ltd Dopamin-d3-receptorantagonistforbindelser
US10828302B2 (en) 2016-03-10 2020-11-10 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
JP7214632B2 (ja) 2016-07-21 2023-01-30 バイオジェン エムエー インク． ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
EP3686196B1 (en) * 2017-09-20 2024-06-12 Hangzhou Innogate Pharma Co., Ltd. Polycyclic compound acting as ido inhibitor and/or ido-hdac dual inhibitor
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
MX2021005698A (es) 2018-11-14 2021-07-07 Janssen Pharmaceutica Nv Metodos sinteticos mejorados para elaborar compuestos heterociclicos fusionados como moduladores del receptor de orexina.
CN112010859B (zh) * 2019-05-30 2022-07-19 中国科学院上海药物研究所 一种并环化合物、其制备方法和用途
PE20220842A1 (es) 2019-08-07 2022-05-24 Janssen Pharmaceutica Nv Metodos sinteticos mejorados para la elaboracion de compuestos de (2h-1,2,3-triazol-2-il)fenilo como moduladores del receptor de orexina
CN112047878B (zh) * 2020-10-15 2022-04-19 郑州猫眼农业科技有限公司 4-溴-6-氯吡啶-2-羧酸的制备方法
WO2024189472A1 (en) 2023-03-14 2024-09-19 Janssen Pharmaceutica Nv Improved synthetic methods of making substituted pyrimidine intermediates for synthesis of orexin receptor modulators

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393424B1 (de) * 1989-04-17 1995-09-27 Bayer Ag Verfahren zur Herstellung von 2,7-Diazabicyclo(3.3.0)octanen
NL9201810A (nl) 1992-10-19 1994-05-16 Dsm Nv Werkwijze voor de omzetting van een olefine of een olefinemengsel.
NO301165B1 (no) 1992-12-25 1997-09-22 Daiichi Seiyaku Co Bicykliske aminderivater og antibakterielle midler inneholdende disse
US5817679A (en) * 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US5478939A (en) * 1994-07-20 1995-12-26 American Cyanamid Company (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives
US5472958A (en) 1994-08-29 1995-12-05 Abbott Laboratories 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
MX9800776A (es) * 1995-07-28 1998-04-30 Abbott Lab Furopiridina, tienopiridina, pirrolopiridina y compuestos de triazina, piridazina y pirimidina relacionados utiles para controlar la transmision sinaptica quimica.
GB9519558D0 (en) * 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
JPH09172344A (ja) 1995-12-19 1997-06-30 Murata Mfg Co Ltd 圧電共振子
US5733912A (en) 1997-02-19 1998-03-31 Abbott Laboratories 7A-heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in controlling chemical synaptic transmission
NZ500645A (en) * 1997-05-30 2001-06-29 Neurosearch As 9-Azabicyclo[3.3.1]non-2-ene and nonane derivatives as cholinergic ligands at nicotinic ACh receptors
CA2289574C (en) * 1997-05-30 2007-04-24 Neurosearch A/S 8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors
GB9722343D0 (en) * 1997-10-22 1997-12-17 British Telecomm Distributed virtual environment
ATE491689T1 (de) * 1997-10-27 2011-01-15 Neurosearch As Heteroaryl diazacycloalkane als cholinergische ligande für nikotin-acetylcholin-rezeptoren
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
WO1999051602A1 (en) * 1998-04-02 1999-10-14 R.J. Reynolds Tobacco Company Azatricyclo[3.3.1.1] decane derivatives and pharmaceutical compositions containing them
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
JP2000026408A (ja) 1998-07-02 2000-01-25 Dai Ichi Seiyaku Co Ltd 対掌体的に純粋なピロリジン誘導体、その塩、それらの製造方法
US6804251B1 (en) 1998-11-12 2004-10-12 Broadcom Corporation System and method for multiplexing data from multiple sources
FR2786769B1 (fr) * 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
TR200102162T2 (tr) * 1999-01-29 2001-12-21 Abbott Laboratories Nikotinik asetilkolin reseptör ligandları olarak diazabisiklik türevler.
EP1177196B1 (en) * 1999-05-04 2004-03-10 Neurosearch A/S Heteroaryl diazabicycloalkanes, their preparation and use
EP1178982B1 (en) * 1999-05-21 2004-06-30 Abbott Laboratories Heterocyclic substituted aminoazacycles useful as central nervous system agents
MXPA02005884A (es) * 1999-12-14 2002-10-23 Neurosearch As Heteroaril-diazabicicloalcanos novedosos.

Also Published As

Publication number Publication date
KR100947188B1 (ko) 2010-03-12
CA2683045A1 (en) 2001-11-01
IL177316A (en) 2010-06-30
CN102863441A (zh) 2013-01-09
CN1440410A (zh) 2003-09-03
AU6655901A (en) 2001-11-07
CA2407094A1 (en) 2001-11-01
JP2012041349A (ja) 2012-03-01
CZ20023765A3 (cs) 2003-02-12
EP1284976A2 (en) 2003-02-26
JP2003531210A (ja) 2003-10-21
KR100961406B1 (ko) 2010-06-09
AU2001266559B2 (en) 2005-03-03
NO324250B1 (no) 2007-09-17
BG110620A (bg) 2010-07-30
BG66151B1 (bg) 2011-08-31
MY137020A (en) 2008-12-31
NO20025107L (no) 2002-12-19
MY145722A (en) 2012-03-30
CN101935322A (zh) 2011-01-05
BG107303A (bg) 2003-07-31
PL358340A1 (en) 2004-08-09
AU2001266559C1 (en) 2005-11-17
TW200909432A (en) 2009-03-01
IL203035A (en) 2010-12-30
CZ302038B6 (cs) 2010-09-15
SK287658B6 (sk) 2011-05-06
EP2298775A1 (en) 2011-03-23
WO2001081347A3 (en) 2002-01-31
HUP0300602A3 (en) 2005-12-28
KR100899950B1 (ko) 2009-05-28
SK16812002A3 (sk) 2003-04-01
SK287273B6 (sk) 2010-05-07
KR20020093955A (ko) 2002-12-16
BR0107246A (pt) 2002-10-01
TWI311137B (en) 2009-06-21
CA2407094C (en) 2009-11-17
NO20025107D0 (no) 2002-10-24
CZ302072B6 (cs) 2010-09-29
HUP0300602A2 (hu) 2003-06-28
IL152231A0 (en) 2003-05-29
CZ301324B6 (cs) 2010-01-13
PL398491A1 (pl) 2012-06-04
CZ302795B6 (cs) 2011-11-16
EP2295437A1 (en) 2011-03-16
TW201141871A (en) 2011-12-01
AR030421A1 (es) 2003-08-20
WO2001081347A2 (en) 2001-11-01
CN100430398C (zh) 2008-11-05
KR20090013833A (ko) 2009-02-05
MY168244A (en) 2018-10-15
KR20090071654A (ko) 2009-07-01
JP4981232B2 (ja) 2012-07-18
TWI323733B (en) 2010-04-21
PE20011305A1 (es) 2001-12-31
MXPA02010594A (es) 2003-05-14
NZ521734A (en) 2004-10-29
TW200617013A (en) 2006-06-01
KR20090121385A (ko) 2009-11-25
KR100947187B1 (ko) 2010-03-12
TWI357903B (en) 2012-02-11
IL177316A0 (en) 2006-12-10

Similar Documents

Publication Publication Date Title
HK1054375A1 (zh) 二氮雙雜環中樞神經系統活性劑
TR200000197T2 (tr) Yeni bileşimler
WO2001076370A3 (en) Anthelmintic combinations
AU7779900A (en) Trifluoromethyl-substituted spirocyclic ketoenols
MY140674A (en) New crystalline form of a triazolo(4,5-d)pyrimidine compound
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
IL190780A0 (en) Heterocyclic substituted aminoazacycles useful as central nervous system agents
AU2001236457A1 (en) Compounds and compositions for delivering active agents
EP1438973A4 (en) MEANS FOR THE TREATMENT OF STRESS-RELATED DISEASES WITH MITOCHONDRIENE BENZODIAZEPINE RECEPTOR ANTAGONISTS
AU2001284985A1 (en) Compounds and compositions for delivering active agents
AU2001272100A1 (en) Use of tgf-beta antagonists to treat or to prevent loss of renal function
WO2003051879A8 (en) Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
CA2284551A1 (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
WO2002015959A3 (en) Compounds and compositions for delivering active agents
AU2001250012A1 (en) Method for the preparation of homo structured mixed proton and organic layered silicates
ID29790A (id) PENGGUNAAN IMIDAZO(1,5-a)-PIRIDO(3,2-e)-PIRAZINON SEBAGAI OBAT
AU2001234273A1 (en) Thiazolopyrimidines and their use as modulators of chemokine receptor activity
WO2002051848A3 (de) Sulfamidothienopyrimidine zur verwendung als phosphodiesterase v-hemmer
CA2372040A1 (en) Imidazodiazepine derivative
WO2002000208A3 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
HUP0303486A3 (en) Compositions containing 3,7-diazabicyclo [3,3,1] compounds as anti-arrythmic compounds agents
MXPA03008894A (es) Uso de compuestos de imidazo[1,2-a]-piridin-3-il-amidas e imidazo [1,2-a]-piridin-3-il-aminas sustituidas como medicamentos.
MXPA02012260A (es) 2-aminoalquil-tieno[2,3-d]pirimidinas.
AU2002212941A1 (en) Novel compounds
BRPI0407541A (pt) combinações e uso de compostos farmaceuticamente ativos selecionados